Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy-Reference-Cited by-同舟云学术

Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy

Published:2016-05-17 Issue:6 Volume:174 Page:859-867
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Martínez Carmen¹,Díaz-López Antonio²,Rodriguez-Calvillo Mercedes³,García-Sanz Ramón⁴,Terol María José⁵,Pérez-Ceballos Elena⁶,Jiménez Maria J.⁷,Cantalapiedra Alberto⁸,Domingo-Domenech Eva⁹,Rodriguez María José¹⁰,Sampol Antonia¹¹,Espeso Manuel¹²,López Francisco-Javier¹³,Briones Javier¹⁴,García Juan F.²,Sureda Anna⁹,

Affiliation:

1. Department of Haematology; Hospital Clínic of Barcelona; Barcelona Spain

2. Pathology Department; MD Anderson Cancer Centre; Madrid Spain

3. Department of Haematology; Complejo Hospitalario de Navarra; Pamplona Spain

4. Department of Haematology; Hospital Clínico of Salamanca; Salamanca Spain

5. Department of Haematology; Hospital Clínico of Valencia; Valencia Spain

6. Department of Haematology; Hospital Morales Messeguer of Murcia; Murcia Spain

7. Department of Haematology; Hospital Germans Trias i Pujol of Barcelona; Barcelona Spain

8. Department of Haematology; Hospital Río Hortega of Valladolid; Valladolid Spain

9. Department of Haematology; Hospital Duran i Reynals of Barcelona; Barcelona Spain

10. Department of Haematology; Hospital Universitario de Canarias; Tenerife Spain

11. Department of Haematology; Hospital Universitari Son Espases of Mallorca; Palma Mallorca Spain

12. Department of Haematology; Complejo Hospitalario Carlos Haya of Málaga; Malaga Spain

13. Department of Haematology; Hospital Ramón y Cajal of Madrid; Madrid Spain

14. Department of Haematology; Hospital de la Santa Creu i Sant Pau of Barcelona; Barcelona Spain

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14133/fullpdf

Reference33 articles.

1. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma;Ansell;New England Journal of Medicine,2015

2. ESHAP is an active regimen for relapsing Hodgkin's disease;Aparicio;Annals of Oncology,1999

3. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804;Bartlett;Annals of Oncology,2007

4. Addition of rituximab to BEACOPPescalated to improve the outcome of early interim PET positive advanced stage Hodgkin lymphoma patients: second planned interim analysis of the HD18 study;Borchmann;Blood,2014

5. Revised response criteria for malignant lymphoma;Cheson;Journal of Clinical Oncology,2007

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab;Leukemia & Lymphoma;2021-01-15

Salvage Therapy for Hodgkin’s Lymphoma: A Review of Current Regimens and Outcomes

;Journal of Blood Medicine;2020-10

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma

;OncoTargets and Therapy;2020-06

4. Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma;British Journal of Haematology;2020-02-12

5. Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies;Therapeutic Advances in Hematology;2020-01